生物制药公司Nuvation Bio宣布，将与全球科学服务巨头赛默飞世尔科技（Thermo Fisher Scientific）建立合作关系，在美国本土进行其靶向药物Ibtrozi®的生产制造。该药物旨在用于治疗ROS1阳性非小细胞肺癌（NSCLC）患者。
此次合作旨在利用赛默飞世尔科技在生物制药合同开发与生产（CDMO）领域的专业能力和规模化设施，以确保Ibtrozi®稳定、高质量的供应链。在美国本土建立生产基地，不仅有助于满足潜在的临床与商业化需求，也可能增强供应链的韧性并缩短产品上市时间。
对于专注于开发肿瘤创新疗法的Nuvation Bio而言，与行业领先的制造伙伴合作是其推进核心管线产品的重要战略步骤。ROS1阳性非小细胞肺癌存在明确的未满足临床需求，Ibtrozi®的开发与生产进展备受关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.